Chongqing Zhifei Biological Products Past Earnings Performance
Past criteria checks 3/6
Chongqing Zhifei Biological Products has been growing earnings at an average annual rate of 28.2%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 38.3% per year. Chongqing Zhifei Biological Products's return on equity is 22.9%, and it has net margins of 14.1%.
Key information
28.2%
Earnings growth rate
28.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 38.3% |
| Return on equity | 22.9% |
| Net Margin | 14.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Chongqing Zhifei Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 53,141 | 7,496 | 3,778 | 989 |
| 31 Dec 23 | 52,918 | 8,070 | 3,508 | 968 |
| 30 Sep 23 | 49,712 | 8,462 | 3,702 | 895 |
| 31 Mar 23 | 40,596 | 7,648 | 3,124 | 907 |
| 01 Jan 23 | 38,264 | 7,539 | 3,016 | 854 |
| 30 Sep 22 | 36,647 | 7,412 | 2,727 | 920 |
| 30 Jun 22 | 35,835 | 8,447 | 2,615 | 778 |
| 31 Mar 22 | 35,567 | 11,193 | 2,489 | 652 |
| 31 Dec 21 | 30,652 | 10,209 | 2,312 | 553 |
| 30 Sep 21 | 25,969 | 9,226 | 1,977 | 319 |
| 30 Jun 21 | 21,368 | 7,287 | 1,838 | 356 |
| 31 Mar 21 | 16,482 | 3,723 | 1,629 | 314 |
| 31 Dec 20 | 15,190 | 3,301 | 1,493 | 300 |
| 30 Sep 20 | 13,971 | 3,082 | 1,539 | 286 |
| 30 Jun 20 | 12,542 | 2,724 | 1,447 | 208 |
| 31 Mar 20 | 10,928 | 2,381 | 1,398 | 186 |
| 31 Dec 19 | 10,587 | 2,366 | 1,346 | 170 |
| 30 Sep 19 | 9,400 | 2,128 | 1,297 | 160 |
| 30 Jun 19 | 8,195 | 1,916 | 1,165 | 167 |
| 31 Mar 19 | 6,684 | 1,694 | 1,041 | 152 |
| 31 Dec 18 | 5,228 | 1,451 | 956 | 143 |
| 30 Sep 18 | 4,068 | 1,234 | 690 | 166 |
| 30 Jun 18 | 2,969 | 943 | 607 | 122 |
| 31 Mar 18 | 2,019 | 632 | 482 | 100 |
| 31 Dec 17 | 1,343 | 432 | 437 | 78 |
| 30 Sep 17 | 942 | 311 | 451 | 0 |
| 30 Jun 17 | 707 | 192 | 406 | 0 |
| 31 Mar 17 | 464 | 34 | 381 | 0 |
| 31 Dec 16 | 446 | 33 | 370 | 0 |
| 30 Sep 16 | 431 | 44 | 353 | 0 |
| 30 Jun 16 | 512 | 101 | 371 | 0 |
| 31 Mar 16 | 660 | 209 | 365 | 0 |
| 31 Dec 15 | 713 | 197 | 369 | 0 |
| 30 Sep 15 | 779 | 172 | 381 | 0 |
| 30 Jun 15 | 805 | 160 | 352 | 0 |
| 31 Mar 15 | 835 | 153 | 346 | 0 |
| 31 Dec 14 | 801 | 148 | 327 | 0 |
| 30 Sep 14 | 777 | 136 | 320 | 0 |
| 30 Jun 14 | 735 | 124 | 310 | 0 |
| 31 Mar 14 | 758 | 132 | 312 | 0 |
| 31 Dec 13 | 780 | 130 | 312 | 0 |
| 30 Sep 13 | 844 | 203 | 261 | 0 |
| 30 Jun 13 | 858 | 209 | 270 | 0 |
Quality Earnings: 300122 has high quality earnings.
Growing Profit Margin: 300122's current net profit margins (14.1%) are lower than last year (18.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300122's earnings have grown significantly by 28.2% per year over the past 5 years.
Accelerating Growth: 300122's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300122 had negative earnings growth (-2%) over the past year, making it difficult to compare to the Biotechs industry average (-2.6%).
Return on Equity
High ROE: 300122's Return on Equity (22.9%) is considered high.